The first generation of GLP-1 agonists are out of patent protection. Teva is producing a generic liraglutide (aka Victoza / Saxenda). Ozempic (semiglutide) and Mounjaro (tirzepatide) have protection until after 2031 in the US, I think it's less in other countries.
alt Hacker News
The first generation of GLP-1 agonists are out of patent protection. Teva is producing a generic liraglutide (aka Victoza / Saxenda). Ozempic (semiglutide) and Mounjaro (tirzepatide) have protection until after 2031 in the US, I think it's less in other countries.